Background {#Sec1}
==========

Autoantibodies against citrullinated proteins (ACPA) are specifically associated with rheumatoid arthritis (RA) and are present prior to the onset of the disease \[[@CR1], [@CR2]\]. ACPA-positive patients are more likely to suffer from a severe form of the disease with enhanced radiological progression \[[@CR3]\]. The core feature of epitopes recognized by ACPA is the non-coding amino acid citrulline (Cit). Accordingly, synthetic (cyclic) citrullinated peptides (CCP) are often used in highly sensitive and specific commercial ELISA kits to detect ACPA \[[@CR4], [@CR5]\]. ACPA recognize a variety of citrullinated antigens - prominent among them being citrullinated α-enolase, vimentin, type II collagen, fibrinogen and histone \[[@CR6], [@CR7]\].

Fibrinogen, a hexameric molecule containing pairs of α, β and γ chains, is the precursor of fibrin and is involved in the clotting cascade \[[@CR8]\]. Citrullinated fibrinogen (cit-Fib) is known to be present in the synovial fluid of patients with RA and autoantibodies against cit-Fib are found both in the sera and synovial fluid of patients with RA \[[@CR8]--[@CR10]\]. Anti-cit-Fib ELISA has been suggested to display similar diagnostic performance to the commercial anti-CCP ELISA \[[@CR11], [@CR12]\].

The exact pathophysiological involvement of cit-Fib and anti-cit-Fib antibodies is not fully understood, but there are several indications that they may have a pathogenic role in RA. For instance, it has been demonstrated that immunization of HLA-DR4-IE transgenic mice with cit-Fib results in the induction of (mild) disease symptoms characteristic of RA \[[@CR13]\]. Circulating immune complexes containing cit-Fib have been found in patients with RA and these immune complexes have been shown to stimulate macrophages to produce TNF-α via the Fcγ receptor and Toll-like receptor 4 in vitro \[[@CR14], [@CR15]\]. Fibrinogen has 81 arginine residues of which two thirds are susceptible to citrullination, although most of these sites do not serve as B cell epitopes \[[@CR16]\]. Several studies have identified and validated some of the cit-Fib epitopes in RA using different approaches \[[@CR8], [@CR16]--[@CR20]\]. Cit-Fib has also been verified as an ACPA target in patients with RA throughout the world \[[@CR21]--[@CR23]\] with recognition of the α subunit peptide 36-52 and the β subunit peptide 60-74 being the most prominent.

This study is based on the cit-Fib peptides previously identified via mass spectrometry of RA synovial fluid \[[@CR24]\], focusing on the immune reactivity against these less-studied peptides. Using synthetic peptides derived from cit-Fib, we established ELISAs to analyze serum from healthy individuals, patients with RA and patients with non-RA conditions, for the presence of autoantibodies against some of the cit-Fib epitopes. The association between these autoantibodies and the two most prominent genetic RA risk factors, HLA-DR shared epitope (SE) alleles and the PTPN22 R620W allele coding for a tyrosine phosphatase variant, was investigated. Finally, anti-cit-Fib-specific B cells in the peripheral blood of patients with RA were characterized and the association with the aforementioned risk alleles was investigated.

Methods {#Sec2}
=======

Patients and healthy subjects {#Sec3}
-----------------------------

Serum samples were collected from 347 patients diagnosed as having established RA according to the ACR criteria \[[@CR25]\]. All patients attended the Rheumatology unit at the Karolinska University Hospital, Stockholm, Sweden, where the serum samples were collected and stored at -80 °C until further use. All the samples were previously assayed for anti-CCP2 antibodies and antibodies against full cit-Fib (cit-Fib protein) \[[@CR10]\]. Additionally, serum samples from 152 healthy subjects and 236 patients with psoriatic arthritis (PSA) or ankylosing spondylitis (AS) were included as healthy and disease controls, respectively (Table [1](#Tab1){ref-type="table"}). The ethical review board of Karolinska University hospital approved this study and all the patients involved gave informed consent.Table 1Characteristics of the patients in the different groupsHealthyDisease controlsPatients with RANumber of individuals152236347Female), *n* (%)107 (70.4)115 (48.7)277 (79.8)Age, median (range)57 (23--71)47 (18--85)58 (21 − 94)Anti-CCP2, *n* (%)5 (3.3)10 (4.2)250 (72.0)Anti-cit-Fib protein, *n* (%)NANA190 (54.9)*RA* rheumatoid arthritis, *CCP* cyclic citrullinated peptides, *cit-Fib* citrullinated fibrinogen, *NA* data not available

HLA-DR and PTPN22 genotyping {#Sec4}
----------------------------

A total of 326 of the 347 patients with RA were previously genotyped for the HLA-DR SE allele \[[@CR6]\] and 322 of the 347 patients with RA were genotyped for the PTPN22 R620W risk allele \[[@CR26]\]. HLA-DRB1\*0101, \*0102, \*0401, \*0404, \*0405 or \*1001 alleles were classified as HLA-shared epitope (HLA-SE) alleles \[[@CR27]\].

ELISA for the detection of IgG against different cit-Fib peptides {#Sec5}
-----------------------------------------------------------------

Biotinylated Fib peptides (Table [2](#Tab2){ref-type="table"}) were synthesized by a solid-phase procedure using fluorenylmethoxycarbonyl (Fmoc) chemistry as described previously \[[@CR28]\]. The peptides were at least 90% pure as deduced from their elution pattern on reversed-phase high performance liquid chromatography (HPLC). Streptavidin-coated high binding capacity 96-well ELISA plates (Thermo Scientific) were coated with the peptides in their native and citrullinated forms at a concentration of 2.5 μg/ml in coating buffer (0.05% Tween-20, 0.1% bovine serum albumin (BSA), Tris-buffered saline). The plates were washed with PBS containing 0.05% Tween-20 after every incubation step. For detection of the antibodies against citrullinated peptides, the serum samples were diluted 1:100 in radioimmunoassay (RIA) buffer (1% BSA, 350 mM NaCl, 10 mM Tris HCl, pH 7.6, 1% (v/v) Triton X-100, 0.5% (weight/volume) sodium deoxycholate, 0.1% sodium dodecyl sulfate). The bound antibodies were detected with horseradish peroxidase-conjugated goat anti-human IgG F(ab')~2~ (Jackson Immuno Research). Bound antibodies were visualized using the chromogenic substrate 3,3′,5,5′-tetramethylbenzidine (TMB, Sigma-Aldrich). The optical density (OD) was then measured at 450 nm with reference at 650 nm subtracted. A standard curve was included in each plate to convert the OD values into arbitrary units.Table 2Sequence of the different fibrinogen alpha peptides in their citrullinated form used in the ELISAPeptideAmino acidPeptide sequenceCit-Fib α 3529-41AEGGGV(Cit)GPRVVEZOCit-Fib α 216,218201-225KDLLPS(Cit)D(Cit)QHLPLIKZOCit-Fib α 263,271256-278QMRMELE(Cit)PGGNEIT(Cit)GGSTSYGZOCit-Fib α 425,426419-432NVSPGT(Cit)(Cit)EYHTEKZO*O* biotin, *Z* 6-aminohexanoic acid

The cutoff value for each of the citrullinated antigens was set to the 98^th^ percentile of values from healthy subjects (*n* = 152). In some cases, samples displayed high reactivity to both a citrullinated peptide and to its native arginine-containing counterpart, thereby distorting the analysis. Therefore, a ratio between the OD values obtained with the peptides containing arginine and citrulline was determined for each sample and samples with a ratio greater than 0.8 were considered negative.

Tetramer production and flow cytometry {#Sec6}
--------------------------------------

The B cell antigen tetramer consists of an R-phycoerythrin (PE)-labeled streptavidin (SA) core and four identical biotinylated peptides. Tetramers were prepared as previously described \[[@CR29]\]. Briefly, the biotinylated cit-Fib peptides used in the ELISA were incubated with SA-PE (Prozyme) at a molar ratio of 10:1. The tetramer fraction was then purified using a 100-kD molecular weight cutoff Amicon Ultra filter (Millipore). The molarity of the tetramer was calculated with the supplier-determined ratio of SA to PE, after measuring the concentration of PE by Nanodrop (Thermo Fischer). The decoy tetramer was prepared, as described above, by incubating the biotinylated native (non-citrullinated) Fib peptides with SA-PE pre-conjugated to Alexa Flour 647 (Molecular Probes Invitrogen). The four α-chain derived Fib peptides were assembled as tetramers separately and then pooled at the time of sample staining. The decoy tetramers were assembled and used in the same manner with the corresponding native Fib peptides.

Tetramer-positive B cells were analyzed in two small cohorts of patients with RA, selected/recruited based on their PTPN22 risk allele status (CC - non risk vs CT - risk). The pilot cohort consisted of cryopreserved peripheral blood mononuclear cells (PBMC) (*n* = 5 individuals, all female, median age 49 (range 40--75), all HLA-DR SE-negative) and the validation cohort consisted of fresh PBMC (*n* = 10 individuals, 7 female/3 male, median age 58 (range 30--69), all HLA-DR SE-positive). PBMC isolated from patients were stained with the decoy and cit-Fib tetramers in buffer containing Fc blocking solution (FcR Blocker Miltenyi Biotec), then passed over a magnetized LS column (Miltenyi Biotec) to enrich for tetramer-binding cells. Both the bound and flow-through fractions were stained with APC-H7-labeled anti-CD3 (SK7), APC-H7-labeled anti-CD14 (MφP9), APC-H7-labeled anti-CD16 (3G8), BV421-labeled anti-CD19 (HIB19), V500-C-labeled anti-CD20 (L27), PE-Cy7-labeled anti-CD27 (M-T271) and FITC-labeled anti-IgD (IA6-2) (all antibodies from BD Biosciences). All the incubation and wash steps were performed using MACS buffer containing 1 mM EDTA and 0.5% BSA in PBS.

Flow cytometry was performed using a 4-laser (405 nm, 488 nm, 561 nm and 640 nm) LSR Fortessa (BD Biosciences) and analyzed with FlowJo software (Tree Star). Fluorescent AccuCheck counting beads (Invitrogen) were used to calculate total numbers of live lymphocytes in the column-bound and flow-through suspensions. The gating strategy for tetramer staining was based on a forward scatter (FSC)/side scatter (SSC) lymphocyte gate and removal of doublets followed by dumping CD3, CD14 and CD16 as depicted in Fig. [3a](#Fig3){ref-type="fig"}, before focusing on the B cell subset.

Statistical analysis {#Sec7}
--------------------

All statistical analyses were carried out using GraphPad Prism (version 6.0) software, SPSS software and Microsoft Excel 2010. Chi square analysis (or Fisher's exact test when appropriate) was performed to analyze the association between the presence of antibody against the cit-Fib peptides and anti-CCP2 antibodies, antibodies against citrullinated full-length Fib (cit-Fib protein), and HLA-SE and PTPN22 risk alleles. *P* values less than 0.05 were considered significant and have not been corrected for multiple comparisons.

Results {#Sec8}
=======

Antibodies against the different citrullinated fibrinogen peptides are present in the serum of patients with RA {#Sec9}
---------------------------------------------------------------------------------------------------------------

Using mass spectrometry analysis \[[@CR24]\], fibrinogen peptides containing the citrulline sites α-35, α-263,271 and α-425,426 had a spectral count 2.5 times higher than controls and were present in the synovial fluid of more patients with RA than controls. All the peptides had a Mascot score greater than 40 and have also been identified by in-vitro citrullination of fibrinogen using human and rabbit PAD enzymes (summarized in \[[@CR16]\]). To assess the detailed anti cit-Fib B cell responses, we used ELISA to test for the presence of antibodies against the four different cit-fibrinogen peptides \[[@CR16], [@CR24]\]. A cohort of healthy subjects was used to determine the cutoff at the 98^th^ percentile for the ELISA and based upon this cutoff, the cit-Fib reactivity in serum from 347 patients with RA was analyzed. We found relatively weak, though frequently present, reactivity in the RA cohort, with 20.2% towards the cit-Fib α-35, 12.5% towards cit-Fib α-216,218, 21.0% towards cit-Fib α-263,271 and 17.0% towards cit-Fib α-425,426 (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Levels and percentage reactivity of serum antibodies against the different citrullinated fibrinogen (*cit-Fib*) peptides. Comparison of the levels of antibodies against the four different cit-Fib peptides in serum from patients and controls (**a**. cit-Fib α35; **b**. cit-Fib α216;218; **c**. cit-Fib α263, 271; **d**. cit-Fib α425, 426). *Horizontal dotted line* indicates the ELISA cutoff for positivity towards the cit-peptide. *Pie charts* (*bottom*) represent the percentage positivity in each cohort. Number of individuals is indicated in the *centre* of the pie chart. *RA* rheumatoid arthritis

Antibodies against the different citrullinated fibrinogen peptides are specific for RA {#Sec10}
--------------------------------------------------------------------------------------

To understand if the presence of antibodies against these cit-Fib targets were specific for RA, we then analyzed serum from a cohort of patients with non-RA arthritis. For this purpose, we analyzed serum from a cohort of 236 patients with PSA and AS: we only identified a few reactive serum samples, mostly with low levels of the different antibodies. Reactivity against the cit- Fib α-35, cit- Fib α-216,218, cit- Fib α-263,271 and cit- Fib α-425,426 in this cohort was found to be 1.0% (*n* = 2), 0.5% (*n* = 1), 0.5% (*n* = 1) and 1.0% (*n* = 2), respectively (Fig. [1](#Fig1){ref-type="fig"}).

Anti-cit-Fib reactivity is predominantly non-overlapping {#Sec11}
--------------------------------------------------------

With regard to overlap between the different epitope reactivity, i.e. whether the same patients presented with more than one anti-cit-Fib antibody, and to the distribution compared to anti-CCP2, we observed that most patients were reactive to a single cit-Fib peptide, although some overlap was seen (Fig. [2](#Fig2){ref-type="fig"}). Still, the cit-Fib response was predominantly in the anti-CCP2-positive patient subset (*p* \< 0.0001).Fig. 2Serum reactivity to multiple citrullinated fibrinogen (*cit-Fib*) epitopes. **a**. *Pie charts* indicate the proportion of serum samples that were reactive with multiple cit-Fib peptides. The total number of individuals is indicated in the *centre* of the pie chart. The *p* value indicates the result from a chi square test comparing the multiple reactivates in anti-citrulline protein antibody (ACPA)-positive vs ACPA-negative individuals. **b**. Illustration of the multiple reactivity seen in individuals positive for antibodies against each cit-Fib peptide. *CCP* cyclic citrullianted peptides

Association of anti-cit-Fib with PTPN22 R620W risk allele {#Sec12}
---------------------------------------------------------

It has been previously shown that the presence of ACPA is associated with the HLA-DR SE alleles and with the PTPN22 R620W risk allele \[[@CR30]\]. We examined the association between these two genotypes and antibodies against the four cit-Fib peptides, antibodies against whole cit-Fib protein and anti-CCP2 antibodies. The association was significant (*p* ≤ 0.05) for antibodies against the four cit-Fib peptides and anti-CCP2 antibodies (Table [3](#Tab3){ref-type="table"}). Also a significant association was observed between the presence of antibodies against all cit-Fib peptides and those against whole cit-Fib protein. No association was observed between the presence of antibodies against any of the cit-Fib peptides and HLA-DR SE. In contrast, an association was observed between the PTPN22 risk allele and seropositivity for cit-Fib α-35 and cit-fibrinogen α-263,271 (Table [3](#Tab3){ref-type="table"}). PTPN22 risk allele carriers had a significant odds ratio ( (OR) 95% CI) for the presence of antibodies against cit-Fib α-35, OR = 1.8 (1.0--3.1) and cit-Fib α-263,271, OR = 2.0 (1.1--3.4) (Table [4](#Tab4){ref-type="table"}).Table 3Associations between cit-Fib reactivity and serological (anti CCP2 and anti-cit-Fib) and genetic risk markers (HLA-DR SE and PTPN22 risk allele)All patients (*n* = 347)Anti CCP2 (*n* = 347)Anti-cit-Fib (*n* = 346)NoYes*P* valueNoYes*P* valueCit-Fib α 3570 (20.2)0 (0)70 (28.0)\<0.00013 (1.9)66 (34.74)\<0.0001Cit-Fib α 216,21844 (12.7)2 (2.1)42 (16.8)0.000113 (8.3)31 (16.32)0.03Cit-Fib α 263,27173 (21.0)1 (1.0)72 (28.8)\<0.00018 (5.1)64 (33.68)\<0.0001Cit-Fib α 425,42659 (17.0)2 (2.1)57 (22.8)\<0.000114 (9)45 (23.68)0.0003Reactivity to at least one cit-Fib peptide168 (48.4)3 (3.1)165 (66.0)\<0.000129 (18.6)138 (72.63)\<0.0001HLA-DR SE (*n* = 326)PTPN22 C1858T (*n* = 322)Cit-Fib α 3570 (20.2)11 (15.1)55 (21.74)0.2138 (17.4)28 (27.18)0.04Cit-Fib α 216,21844 (12.7)12 (16.4)30 (11.86)0.3032 (14.8)9 (8.74)0.14Cit-Fib α 263,27173 (21.0)13 (17.8)57 (22.53)0.3939 (17.8)30 (29.13)0.02Cit-Fib α 425,42659 (17.0)10 (13.7)46 (18.18)0.3734 (15.5)23 (22.33)0.14Reactivity to at least one cit-Fib peptide168 (48.4)34 (46.6)124 (49.01)0.7199 (45.2)58 (56.31)0.06Anti-cit Fib protein190 (54.9)29 (40.3)147 (58.1)0.01106 (48.6)69 (67.0)0.003Data represent the numbers (percentage) and *p* values (uncorrected for multiple comparisons). *Cit-Fib* citrullinated fibrinogen, *CCP* cyclic citrullinated peptides, *SE* shared epitope Table 4Table shows the odds ratio of reactivity against different cit-Fib peptides and genetic risk allels in RA (HLA-DR SE and PTPN22 risk allele)Cit-Fib α 35Cit-Fib α 216,218Cit-Fib α 263,271Cit-Fib α 425,426Cit-Fib proteinOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueSE1.6 (0.8--3.2)0.210.7 (0.3--1.4)0.311.3 (0.7--2.6)0.391.4 (0.7--2.9)0.372.1 (1.2--3.5)0.008PTPN221.8 (1--3.1)0.040.6 (0.3--1.2)0.142.0 (1.1--3.4)0.021.6 (0.9--2.8)0.142.1 (1.3--3.5)0.002*cit-Fib* citrullinated fibrinogen, *RA* rheumatoid arthritis, *SE* shared epitope

Visualization of cit-Fib-reactive B cells by tetramer technology {#Sec13}
----------------------------------------------------------------

Based on data suggesting a role for PTPN22 in the negative selection of autoreactive B cells \[[@CR31]\], we hypothesized that PTPN22 risk allele carriers in our cohort may have an expanded population of cit-Fib reactive B cells relative to non-risk allele carriers. To test this, we constructed B cell antigen tetramers for quantification and comparison of tetramer-positive B cells in PTPN22 risk allele non-carrier (CC) and carrier (CT, TT) patients with RA. Only CD19^+^ CD20^+^ B cells were included in the tetramer analyses (Fig. [3a](#Fig3){ref-type="fig"}). Analysis of frozen PBMC from five patients with RA (three CC and two CT) showed a trend in increased frequency of tetramer-positive B cells in the patients carrying the PTPN22 risk allele (Fig. [3b](#Fig3){ref-type="fig"}). To validate this finding, we recruited ten additional patients with RA (five CC and five CT PTPN22 allele carriers) and found a similar trend for tetramer-positive B cells with individuals carrying the PTPN22 risk allele (Fig. [3c](#Fig3){ref-type="fig"}).Fig. 3B cell antigen tetramer analysis in individuals with PTPN22 risk allele. **a**. Gating strategy for identification of citrullinated fibrinogen (*cit-Fib*) (pooled tetramers from four α-chain-derived Fib peptides) reactive B cells from peripheral blood mononuclear cells (PBMC). Cells were gated on forward scatter /side scatter to select for lymphocytes and removal of doublets followed by dumping of CD3^+^ CD14^+^ and CD16^+^ cells. All remaining tetramer analysis was performed on CD19^+^ CD20^+^ B cell subsets. **b**. Cit-Fib tetramer analysis in PBMC (frozen) from 5 patients with rheumatoid arthritis (RA), who served as a pilot cohort. *CC* PTPN22 risk allele non-carriers, *CT* risk carriers. Median difference between the two groups was not statistically significant. **c**. Cit-Fib tetramer analysis in PBMC (fresh) from 10 patients with RA, who served as a validation cohort. Median difference between the two groups was not statistically significant

Discussion {#Sec14}
==========

Citrullination of proteins is a posttranslational modification that in susceptible individuals may lead to immune activation, autoantibody production and eventually development of RA \[[@CR22]\]. Detection of these antibodies is generally performed with commercial kits developed as diagnostic tools to catch a large array of ACPA specificities. Growing evidence however indicates that a more refined characterization of the ACPA response is needed to define disease subgroups with distinct clinical phenotypes and genetic associations \[[@CR32]\]. Here, we characterized serum reactivity against four cit-Fib peptides originally identified by mass-spectrometry analysis of RA synovial fluid. The patient samples represented long-standing RA in need of joint effusions, and as a clinical comparison we used serum samples from equally long-standing psoriatic or spondyloarthritis at time points when patients underwent joint effusions. Antibodies against these citrullinated peptides were specific for RA and show distinct genetic association with PTPN22 but not HLA-SE risk alleles. The data generated represent established RA, and earlier disease stages were not analyzed in the present study.

Citrullinated fibrinogen is one of the first and most well-characterized autoantigens in RA \[[@CR33]\]. During the last few years, several new citrullinated proteins have been identified and added to the growing list of potential autoantigens in RA \[[@CR34]--[@CR38]\]. Fibrinogen is elevated in the serum of patients with RA compared to controls \[[@CR39]\] and elevated cit-Fib that is citrullinated on fibrin(ogen) has been identified using different techniques, and some of them have been shown to contain ACPA-targeted epitopes \[[@CR8], [@CR17]--[@CR19], [@CR40]\]. Using unbiased mass spectrometry, we have previously identified several cit-Fib peptides as potential antigenic epitopes in RA \[[@CR24]\]. We were able to identify serum autoantibodies directed against these citrullinated peptides in patients with RA but not in other types of chronic inflammatory joint disease.

Identification of multiple distinct B cell epitopes recognized by the immune system suggests that loss of B cell tolerance towards cit-Fib might play an important role in development of the disease. The antibody reactivity in the present study was relatively less frequent, but was confined to the seropositive (CCP) RA and provides an addition to the growing family of ACPAs. Their low frequency excludes the possibility of substantiating any clinical and pathological importance at this stage, but instead sheds light on the dysregulated B cell compartment in seropositive RA. A limitation of our study is related to exclusion of those samples reacting with the native peptide that might result in underestimation of the real frequency of these antibodies in patients with RA. This dual reactivity to native and citrullinated self-antigen could indeed be biologically significant and relevant to RA pathogenesis. Further analysis is needed in order to clarify this issue.

Previous reports have shown that antibodies against cit-vimentin and cit-α-enolase and to a lesser extent cit-Fib are associated with presence of HLA-DR shared epitope \[[@CR22]\]. We were not able to identify any association between autoantibody reactivity towards our fibrinogen peptides and the HLA-DR shared epitope. Taken together, these data may suggest that ACPA towards some cit-Fib antigens might not arise via classical T cell help to autoreactive B cells, but instead in a more innate or T cell independent fashion. In this context it has been demonstrated that the autoimmune risk allele PTPN22 promotes survival of autoreactive B cells in both RA and type-1 diabetes mellitus by evading the tolerance checkpoints \[[@CR31], [@CR41], [@CR42]\].

More recently, PTPN22 and TNF receptor-associated factor (TRAF)3 have been put forward as inhibitors of IL-6R signaling in B cells and plasma cell differentiation \[[@CR43]\]. It is intriguing to think that the functional polymorphism in PTPN22 could influence this pathway. Obviously, the association between PTPN22 and the autoantibodies we study could also be indirect; the PTPN22 risk allele has been extensively studied in T cell function and could influence the number of follicular helper T cells, which could subsequently increase B cells and antibody production, as demonstrated in mice \[[@CR44]\]. We observed association between the PTPN22 risk allele and autoantibodies against two of the cit-Fib epitopes, although our analysis may have been underpowered to find association for the remaining two sub-specificities. Additional factors directly stimulating B cells to produce antibodies, such as B cell activating factor (BAFF, a.k.a. BLyS) \[[@CR45]\] or type I IFN \[[@CR46]\] might also play a role, but were not analyzed here.

Historically, ELIspot has been the assay of choice to enumerate and visualize antigen-specific B cells, and represents a very sensitive assay system. More recently, the wish to isolate the antigen-specific B cells has led to development of complementary technologies based on flow cytometry. One setup is based on antigens being coupled to beads and then used to stain B cells \[[@CR47]\], and in another setup large antigens could be directly coupled to fluorochromes and used as staining reagents \[[@CR48], [@CR49]\]; last, for peptide-antigens, tetramerization of biotinylated peptides before labeling to create so-called B cell tetramers has been utilized \[[@CR50]\]. The parallel use of a decoy tetramer allows the purging of false-positive events making this technology robust, and this approach has already been employed to study cit-specific B cells in RA \[[@CR51], [@CR52]\].

Utilizing B cell tetramer technology in the present study, we were able to identify cit-Fib reactive B cells in patients with RA and with a trend to higher frequency in PTPN22 risk allele carriers. Though the data were not statistically significant and were limited by there being few data points (frozen cohort, *n* = 5 and fresh cohort, *n* = 10), nevertheless they show a trend that was reproducible in two independent analyses (frozen and fresh cohort). This is in line with previous observations showing the presence of more autoreactive B cells in PTPN22 risk allele carriers with RA and type-1 diabetes mellitus \[[@CR31]\]. In this study we used pooled tetramers from the four cit-Fib antigens, because the limited availability of cells from each patient did not allow us to use them separately. Therefore, our data do not provide information on the relative number of the different cit-Fib reactive B cells in each patient sample. Clearly, the technology can also be utilized to study more common ACPA specificities in RA, but that was outside the scope of this study.

Conclusion {#Sec15}
==========

In this study we have extended the family of ACPA targeting citrullinated fibrinogen. Four minor B cell epitopes on the alpha chain of fibrinogen were validated, and patients with RA displayed mainly non-overlapping immune reactivity to these. The RA genetic risk factor PTPN22 was associated with the new cit-Fib reactivity. We also demonstrated the feasibility of visualizing antigen-specific B cells by tetramer technology, which opens up the path for isolation and further characterization of the autoimmune B cells response in RA.
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